Methazolamide
Systematic (IUPAC) name
N-(3-Methyl-5-sulfamoyl-3H-1,3,4-thiadiazol-2-ylidene) ethanamide
Identifiers
CAS number	554-57-4
ATC code	S01EC05
PubChem	4100
DrugBank	APRD00740
Chemical data
Formula	C5H8N4O3S2
Mol. mass	236.274 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	55%
Metabolism	?
Half life	14 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	℞-only(US)
Routes	Oral

Methazolamide (Neptazane) is a carbonic anhydrase inhibitor.

References

• Iyer G, Bellantone R, Taft D (1999). "In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics.". J Pharmacokinet Biopharm 27 (1): 45–66. doi:10.1023/A:1020630712388. PMID 10533697. 
• RxList. "Neptazane". Retrieved on August 20, 2006.
• Shirato S, Kagaya F, Suzuki Y, Joukou S (1997). "Stevens-Johnson syndrome induced by methazolamide treatment.". Arch Ophthalmol 115 (4): 550–3. PMID 9109770. 
• Skorobohach B, Ward D, Hendrix D (2003). "Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs.". Am J Vet Res 64 (2): 183–7. doi:10.2460/ajvr.2003.64.183. PMID 12602587. 

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.